Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
88 hedge funds and large institutions have $212M invested in Bellicum Pharmaceuticals, Inc. in 2017 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 41 increasing their positions, 16 reducing their positions, and 9 closing their positions.
156% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 16
90% more call options, than puts
Call options by funds: $3.59M | Put options by funds: $1.89M
67% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 9
5% more funds holding
Funds holding: 84 → 88 (+4)
2% less capital invested
Capital invested by funds: $216M → $212M (-$3.89M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$4.3M |
| 2 |
BlackRock
New York
|
+$1.57M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$1.48M |
| 4 |
Morgan Stanley
New York
|
+$1.28M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management III
Larkspur,
California
|
-$5.29M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.92M |
| 3 |
JP Morgan Chase
New York
|
-$2.14M |
| 4 |
Millennium Management
New York
|
-$1.49M |
| 5 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$1.24M |
BLCM Hedge Fund Activity: Q3 2017 in Review
88 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q3 2017, worth a combined $212M — down 1.8% from $216M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new BLCM positions and 9 closed out — a net gain of 6 holders — while 41 added to existing stakes and 16 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $4.3M. The largest seller was Foresite Capital Management III, exiting entirely with an estimated $5.29M sold.
- 88 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q3 2017, up from 84 in Q2 2017.
- Funds reported $212M of Bellicum Pharmaceuticals, Inc. stock for Q3 2017, down 1.8% quarter-over-quarter.
- 15 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q3 2017 and 9 closed out, a net change of +6 holders.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q3 2017 was Point72 Asset Management, an estimated $4.3M added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q3 2017 was Foresite Capital Management III, an estimated $5.29M sold.
Based on aggregated 13F filings for Q3 2017.